Publications by authors named "Christian Knoop"
Article Synopsis
- - Psoriasis is linked to lower life expectancy due to systemic inflammation, and a study analyzed the neutrophil-to-lymphocyte ratio as a marker of this inflammation during treatment with two types of biologic drugs.
- - Results showed that the neutrophil-to-lymphocyte ratio significantly decreased within 3 months and remained low for at least 33 months, with greater reductions in patients receiving tumour necrosis factor-α antagonists compared to those on interleukin-12/23 antagonists.
- - The findings indicate that tumour necrosis factor-α antagonist treatment and initial neutrophil-to-lymphocyte ratios are important predictors of lower cardiovascular risk during psoriasis treatment, highlighting distinct effects of different drug classes
Article Synopsis
- The Psoriasis Area and Severity Index (PASI) is commonly used to evaluate psoriasis treatments, but its effectiveness as a measure of systemic disease in individual patients hasn't been systematically studied.* -
- A retrospective study involving 186 treatments for psoriasis found weak-to-moderate correlations between PASI scores and systemic inflammation biomarkers like the neutrophil-to-lymphocyte ratio and C-reactive protein.* -
- While PASI can indicate levels of systemic inflammation, it should not replace laboratory tests for more accurate evaluations, especially in patients with concurrent conditions like psoriatic arthritis.*
Article Synopsis
- * A study showed that adding methotrexate increased the risk of mild laboratory adverse events, with notable decreases in blood cell counts and an increase in liver enzyme levels (GPT).
- * Serious laboratory side effects (grades 3-4) were observed in about 9.5% of patients using methotrexate compared to 5.2% without it, leading to potential discontinuation of methotrexate in some cases due to these side effects.
Only limited data on laboratory parameter dynamics and safety under prolonged biologic treatment in a "real-world" scenario are available for recommendations on screening and monitoring. This study is a retrospective analysis of routine parameter dynamics and laboratory adverse events (LAE) in psoriasis patients on long-term treatment (n = 199) with tumour necrosis factor (TNF)-α-antagonists (adalimumab, etanercept), and the interleukin (IL)12/23-antagonist ustekinumab. Overall, neutrophil (PMN) counts (-11%) and triglycerides (+9%) changed considerably.
View Article and Find Full Text PDFBackground: Adalimumab and Etanercept are TNF-α antagonists commonly used for treatment of moderate-to-severe psoriasis and psoriatic-arthritis. Reliable instruments to assist the selection of patients for a specific treatment in a real-world scenario are unavailable.
Objective: To identify patient characteristics and baseline laboratory parameters predicting response to Adalimumab- and Etanercept-treatment.